However, the serum level of anti-ENO1 Ab in late-stage patients with lung or breast cancer has been found to be lower as compared to those in healthy donors, and the level of anti-ENO1 Ab in advanced stage NSCLC patients has been shown to be lower than that of early-stage patients [14]. Here, ENO1 is linked to breast cancer.